Collaborations Pharmaceuticals, Inc.
Fuquay Varina, NC
- UEI
- EFJCLL37KKH3
- CAGE
- 7BGW7
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 5616 Hilltop Needmore Rd, Fuquay Varina, NC 27526, USA
- Website
- collaborations.com
- Founded
- 2008
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Consumer Discretionary
- Media
- Movies & Entertainment
- SIC code
- 78 Motion Pictures
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $1,999,195 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Is to develop pan-influenza inhibitors targeting the PA endonuclease from the viral replication complex by… | National Institute of Allergy and Infectious Diseases (NIH) | $1,999,195 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Psychogenics Inc. | R43MH134716 | $164,949 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Emmune Inc. | Cambridge, MA | — |
| Praeventix LLC | Exton, PA | — |
| Therapeutic Systems Research Laboratories | Ann Arbor, MI | — |
| Neovaxsyn Inc. | Ames, IA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Autonomous Therapeutics Inc. | Silver Spring, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Collaborations Pharmaceuticals, Inc., a small-business for-profit pharmaceutical company based in Fuquay Varina, North Carolina, develops novel antivirals, enzyme replacement therapies, and psychoplastogen compounds as a prime recipient on federal research grants from the National Institutes of Health, with 96% of recent awards originating as grant funding rather than contract primes.
The company's federal grant footprint concentrates within NIH institutes studying infectious disease, neurology, and toxicology. The National Institute of Allergy and Infectious Diseases (NIAID) has funded four awards totaling $2 million in combined potential value, including a $1.999 million Small Business Innovation Research Phase II contract (awarded September 29, 2025, completion December 29, 2026) for development of pan-influenza inhibitors targeting the viral PA endonuclease, with demonstration of pyronaridine as a single-dose Ebola treatment in non-human primates. NIAID also awarded $306,870 on September 1, 2026 (completion August 31, 2027) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for in vitro metabolic assessment of a novel anti-HIV compound with reduced neurotoxicity, including combination antiviral testing with cabotegravir and development of sustained-release formulation to support Phase II clinical advancement. The National Institute of Neurological Disorders and Stroke funded a three-award portfolio including a March 8, 2024 project grant for manufacture of an intracerebroventricular enzyme replacement therapy for CLN1 Batten disease (completion February 28, 2026), conducting preclinical development of recombinant palmitoyl-protein thioesterase-1 (PPT1) in CHO cells with manufacturing support from STC Biologics as a contract development and manufacturing organization. The National Institute of Environmental Health Sciences awarded two project grants for machine-learning approaches to predict acetylcholinesterase inhibition to support organophosphorus compound threat assessment and virtual screening (December 10, 2021, running through June 30, 2027). The National Institute on Drug Abuse funded an April 15, 2022 project grant (completion April 14, 2024) to use generative machine learning to design novel psychoplastogen analogs for opioid abuse treatment, targeting 5-HT2A receptor specificity with improved ADME properties.
Twelve distinct NIH customer institutes account for the vendor's recent award activity. Three awards reach ultimate completion within the next twenty-four months, carrying $2 million in combined potential value and presenting recompete opportunity. The vendor holds a single grant sub-award role as a subrecipient to Psychogenics Inc. on an April 15, 2023 sub-award for machine-learning model development using SmartCube bioactivity data and multiple algorithms to predict phenotypic output from structural descriptors. Collaborations Pharmaceuticals' award trajectory is sparse across the past five years — one award in 2022, two in 2023, one each in 2024, 2025, and 2026 — reflecting a research-stage small business focused on early-stage pharmaceutical discovery and preclinical development rather than large-scale federal contracting operations.
Quick answers
Is Collaborations Pharmaceuticals, Inc. registered in SAM.gov?
Yes. Collaborations Pharmaceuticals, Inc.'s SAM.gov registration is active through December 18, 2026.
How much has Collaborations Pharmaceuticals, Inc. received in federal contracts?
Federal contracts obligated $1,999,195 to Collaborations Pharmaceuticals, Inc. in fiscal year 2025.
How does Collaborations Pharmaceuticals, Inc. rank among federal contractors?
Collaborations Pharmaceuticals, Inc. ranked #91 in PSC AN12 in FY2025.
What is Collaborations Pharmaceuticals, Inc.'s most recent federal award?
Collaborations Pharmaceuticals, Inc.'s most recent federal grant award is Long-term formulation for combination antiviral treatment of HIV (R43AI191982), from National Institute of Allergy and Infectious Diseases (NIH), on September 1, 2026.
On GovTribe
See Collaborations Pharmaceuticals, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors